How Maxion’s KnotBody® Platform Is Changing the Way We Treat the ‘Undruggable’

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership.In this episode, we cover:How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseasesWhy conviction, speed, and storytelling are non-negotiable in translational drug developmentLessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnershipsWhat investors really look for - and how Maxion secured a competitive Series A in a tough marketHow to hire and scale for scientific excellence without losing agility or collaborationTune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentArndt SchotteliusCEO at Maxion TherapruticsLinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:46 Translational Science08:55 Lessons in Biotech Leadership25:23 Maxion - Culture and Roundup#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.